Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Melanoma

Clinical and regulatory intelligence for Melanoma with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
7
Catalysts
0
Assets
4

Relevant assets

biobank →
CMP-001 →
Keytruda →
Nivolumab →

Relevant companies

Bristol-Myers Squibb →
Merck →
oncology pharmaceutical companies →
Regeneron →

Recent signals(7)

ClinicalJune 20, 2026

MITF-Driven Plasticity in Melanoma: Key to Overcoming Therapy Resistance

MITF-dependent phenotype switching is identified as a central mechanism enabling melanoma cells to escape therapy.

ClinicalJune 19, 2026

Gut Microbial Markers Linked to Immunotherapy Response in Melanoma Identified in Cross-Cohort Study

A cross-cohort analysis identified 527 metagenome-assembled genomes associated with immunotherapy response in melanoma patients, including specific bacterial species linked to treatment outcomes.

ClinicalJune 17, 2026

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

A novel lactylation-related prognostic model (CM-LP11) effectively stratifies cutaneous melanoma patients into high- and low-risk groups based on overall survival.

ClinicalJune 16, 2026

CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial

A Phase 2/3 study is evaluating CMP-001 in combination with nivolumab against nivolumab monotherapy in advanced melanoma.

ClinicalJune 16, 2026

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death in high-risk melanoma patients.

ClinicalJune 14, 2026

New Biobank Established for Cutaneous Melanoma and Non-Melanoma Research

A new clinical trial is set up to create a biobank of human body material and clinical data from melanoma and non-melanoma patients.

ClinicalJune 12, 2026

Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma

A first-in-human phase I/IIa trial is evaluating the safety and efficacy of b]VMT01, an alpha-particle therapy, in combination with nivolumab for advanced melanoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Melanoma →
Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.